Governo afasta regresso ao IVA reduzido para os ares condicionados

[Jesse James]

Bem bom esse link, obrigado!

[Crómio]

Obrigado Luka, já encontrei:

Resistance and Support types and strength
• Support and resistance types vary from Single (S), Double (D), Triple (T) and more than Triple (T+). (S,D,T,and T+ are the labels used on the 6 month chart)
• The type refers to the number times a stock has visited that resistance or support area over the past 6 months (Single=1 time, Double=2 times, Triple=3 times, Triple+= more than 3 times). The more times a stock has visited a particular price area in the past the stronger the resistance or support.
• Also provided is a strength number which varies from 1-10. This number represents the amount of accumulation or distribution used to create that support or resistance.
• Weaker resistance and support levels created with light distribution or accumulation have strength values from 1-3.

Abraço

[Luka!]

Também estou curioso.

A única coisa que sei é que quanto mais toques tiver, mais efectiva é

aqui fica a fonte :

http://www.stockconsultant.com/consultn ... 93607#ttop

[Jesse James]

Também estou curioso.

A única coisa que sei é que quanto mais toques tiver, mais efectiva é

[Crómio]

Boas!

TARGET 1 RESISTANCE +7.5% at 48.26 ± 1.16, type double, strength 8

Alguém me pode esclarecer duas coisas nestes dados:

O que é uma resistência "double type".
Como se define a força de uma resistência?

Existe algum documento que possa estudar referente a isto?

Obrigado.

[Luka!]

CMED:
Forte crescimento, e depois de uma baixa recente que a levou dos 55 aos 45$ , motivada por uma emissao de papel (reservada a crescimento externo).

aqui lhes deixo:
FUNDAMENTALS >>

No Slowdown for China Medical
By Brian Orelli
August 5, 2008 Comment (1) Recommend (3)
The great Chinese crash of 2008 hasn't hit China Medical Technologies (Nasdaq: CMED). Last Friday, the company was trading 6.6% higher than where it ended 2007.

China Medical Technologies turned in another growth-filled quarter yesterday with revenue up 50% year over year, and net income up an even more impressive 79%. To judge by the 3.5% stock drop, investors were looking for more, but the shares have recovered as of this writing.

A lot of that bottom-line growth can be attributed to the jump in gross margins, from 57.5% last year to 69.1% this year. The company has reduced its focus on being the middleman for the microscopes used to run its fluorescent in situ hybridization (FISH) tests. It's instead letting the hospitals buy the microscopes directly from the manufacturers and focusing on selling the higher-margin reagents for both FISH and enhanced chemiluminescence immunoassay (ECLIA).

That's what I like about China Medical Technologies. It's shifted away from focusing solely on its High Intensity Focused Ultrasound (HIFU) tumor therapy systems that don't provide any meaningful recurring revenue. And it's moved toward high-margin, consumable diagnostic tests that can be sold over and over again to hospitals.

The growth story for the ECLIA and FISH tests isn't over either. China Medical has 20 different ECLIA tests under review by the Chinese FDA, as well as some FISH tests. These include a test to see if Genentech's (NYSE: DNA) Herceptin or GlaxoSmithKline's (NYSE: GSK) Tykerb, both for treating breast cancer, will be effective.

With doctors' increased focus on targeted medicine and infectious diseases, China Medical and other diagnostic-test makers like Myriad Genetics (Nasdaq: MYGN), Cepheid (Nasdaq: CPHD), and Genzyme (Nasdaq: GENZ) should benefit greatly. A high-growth industry in a (still) high-growth location seems like a long-term winning combination for China Medical Technologies.

INCOME STATEMENT >>>
http://finance.yahoo.com/q/is?s=CMED&annual

TECHNICAL ANALYSIS >>

Probability - Intermediate trend bullish, Uptrend.

TRADE QUALITY 95%, Excellent
Good trade quality is a combination of good profit, profit/loss ratio and target potential.

TARGET 1 Price: 52.39 Profit: 16.7% , for a typical rally.
Stop Limit/Trailing Stop Limit: 42.88 Loss: 4.5%
Profit/Loss Ratio: 3.7 : 1 - Good

TARGET 1 POTENTIAL Good, there are 1 resistance areas on the way to Target 1.
Stocks may quickly rise to Targets when there are not many resistance areas blocking the way.

TARGET 1 RESISTANCE +7.5% at 48.26 ± 1.16, type double, strength 8
+16.7% at 52.39 is Target 1